首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Activated plasmacytoid dendritic cells act synergistically with hepatitis B core antigen-pulsed monocyte-derived dendritic cells in the induction of hepatitis B virus-specific CD8 T-cell response.
【24h】

Activated plasmacytoid dendritic cells act synergistically with hepatitis B core antigen-pulsed monocyte-derived dendritic cells in the induction of hepatitis B virus-specific CD8 T-cell response.

机译:活化的浆细胞样树突状细胞与乙型肝炎核心抗原脉冲单核细胞衍生的树突状细胞协同作用,诱导乙型肝炎病毒特异性CD8 T细胞应答。

获取原文
获取原文并翻译 | 示例
       

摘要

It is important to further improve the efficiency of hepatitis B core antigen-pulsed monocyte-derived dendritic cell (core-DC) vaccine in clinical immunotherapy for chronic hepatitis B virus (HBV) infection in humans. Our study shows that CpG-treated plasmacytoid dendritic cells (pDCs) can efficiently promote core-DC terminal maturation and increase interleukin-12 production. These CpG-activated pDCs can act synergistically in vitro with core-DCs in inducing autologous HBV-specific CD8 T-cell proliferation and interferon (IFN)-gamma production. This promotion was mainly dependent on pDC-derived IFN-alpha, because blockade of IFN-alpha nearly completely aborted the effects of pDCs on core-DCs. In addition, the supernatants derived from CpG-treated peripheral blood mononuclear cells can also effectively improve the aforementioned maturation and function of core-DCs. These findings will facilitate a better understanding of how the pDCs regulate myeloid dendritic cell-mediated immune responses, and highlight the notion that manipulating pDCs might have implications in DC vaccine therapy for patients with chronic hepatitis B.
机译:重要的是,在用于人类慢性乙型肝炎病毒(HBV)感染的临床免疫疗法中,进一步提高乙型肝炎核心抗原脉冲单核细胞衍生的树突状细胞(core-DC)疫苗的效率。我们的研究表明,CpG处理的浆细胞样树突状细胞(pDC)可以有效地促进核心DC末端成熟并增加白介素12的产生。这些CpG激活的pDC可以在体外与核心DC协同作用,诱导自体HBV特异性CD8 T细胞增殖和干扰素(IFN)-γ产生。这种促进主要取决于pDC衍生的IFN-α,因为对IFN-α的封锁几乎完全终止了pDC对核心DC的作用。另外,源自CpG处理的外周血单核细胞的上清液也可以有效地改善核心DC的上述成熟度和功能。这些发现将有助于更好地了解pDC如何调节髓样树突状细胞介导的免疫反应,并强调以下观点:操纵pDC可能会对慢性乙型肝炎患者的DC疫苗治疗产生影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号